Scarica l'app Stockscreener
11.35
13.27%
1.33
Pre-mercato:
11.35
Precedente Chiudi:
$10.02
Aprire:
$9.73
Volume 24 ore:
56,489
Relative Volume:
0.97
Capitalizzazione di mercato:
$106.62M
Reddito:
-
Utile/perdita netta:
$-105.61M
Rapporto P/E:
-0.5023
EPS:
-22.5948
Flusso di cassa netto:
$-45.73M
1 W Prestazione:
+17.25%
1M Prestazione:
+98.43%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$9.51
$11.71
Intervallo di 1 settimana:
$8.88
$11.71
Portata 52W:
$4.21
$14.21
Leonabio Inc Stock (LONA) Company Profile
Nome
Leonabio Inc
Settore
Industria
Telefono
(425) 620-8501
Indirizzo
18706 NORTH CREEK PARKWAY, SUITE 104, BOTHELL
Compare LONA vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LONA
Leonabio Inc
|
11.35 | 106.62M | 0 | -105.61M | -45.73M | -22.59 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Leonabio Inc Stock (LONA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-26 | Iniziato | Cantor Fitzgerald | Overweight |
| 2026-02-19 | Aggiornamento | Mizuho | Neutral → Outperform |
| 2024-09-19 | Downgrade | Mizuho | Outperform → Neutral |
| 2024-09-04 | Downgrade | BTIG Research | Buy → Neutral |
| 2024-09-04 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2024-09-04 | Downgrade | Rodman & Renshaw | Buy → Neutral |
| 2024-08-19 | Iniziato | Rodman & Renshaw | Buy |
| 2022-10-17 | Aggiornamento | JMP Securities | Mkt Perform → Mkt Outperform |
| 2022-07-07 | Iniziato | Mizuho | Buy |
| 2022-06-23 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2022-06-23 | Downgrade | Jefferies | Buy → Hold |
| 2022-06-23 | Downgrade | Stifel | Buy → Hold |
| 2022-05-10 | Iniziato | BTIG Research | Buy |
| 2022-04-21 | Iniziato | Berenberg | Buy |
| 2021-12-15 | Iniziato | Goldman | Neutral |
| 2020-10-13 | Iniziato | Goldman | Buy |
| 2020-10-13 | Iniziato | JMP Securities | Mkt Outperform |
| 2020-10-13 | Iniziato | Jefferies | Buy |
| 2020-10-13 | Iniziato | Stifel | Buy |
Mostra tutto
Leonabio Inc Borsa (LONA) Ultime notizie
Leonabio Warns of Major Financial and Operational Risks in Lasofoxifene Program Integration - TipRanks
[EFFECT] LeonaBio, Inc. SEC Filing - Stock Titan
LeonaBio (NASDAQ: ATHA) registers 58.5M shares; warrants could yield $146M - stocktitan.net
LeonaBio (ATHA) clears resale of 5.5M warrant shares for Sermonix - stocktitan.net
LeonaBio (NASDAQ: LONA) files resale registration for PIPE warrant holders - stocktitan.net
LeonaBio (NASDAQ: ATHA) leans on breast cancer and ALS drugs - stocktitan.net
LeonaBio (NASDAQ: ATHA) expands Sermonix deal disclosure and ELAINE-3 trial spend - stocktitan.net
LeonaBio Inc reports results for the quarter ended December 31Earnings Summary - TradingView
LeonaBio Reports 2025 Financial Results, Acquires Lasofoxifene License, and Advances Clinical Pipeline for Metastatic Breast Cancer and ALS 123 - Minichart
LeonaBio Updates Investors on 2025 Results and Strategy - TipRanks
LeonaBio (NASDAQ: LONA) boosts cash to fund Phase 3 breast cancer drug - Stock Titan
LeonaBio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
LeonaBio, Inc. announced that it has received $89.724073 million in funding - MarketScreener
LeonaBio (LONA) Stock Analysis Report | Financials & Insights - Benzinga Japan
LeonaBio, Inc. Adopts 2026 Equity Incentive Plan and Amends Certificate of Incorporation – SEC 8-K Filing March 2026 - Minichart
LeonaBio shareholders approve equity plan and increase in authorized shares - Investing.com India
Form 8K LeonaBio Inc For: 19 March - Investing.com
LeonaBio Expands Share Authorization to Support Future Financing - TipRanks
LeonaBio (ATHA) wins approval for 2026 equity plan and major share increase - Stock Titan
LONA: LeonaBio, Inc.Options Chain - Zacks Investment Research
LeonaBio, Inc. (prev. ATHA) (LONA) Stock Price Prediction for 2026, 2030-2040 - Traders Union
[DEFR14A] LeonaBio, Inc. Revised Proxy Statement - Stock Titan
Renninger, LeonaBio CFO, sells $4.9k in LONA stock - Investing.com Nigeria
LeonaBio CEO Litton sells $27,687 in shares By Investing.com - Investing.com India
LeonaBio CEO Litton sells $27,687 in shares - Investing.com South Africa
Renninger, LeonaBio CFO, sells $4.9k in LONA stock By Investing.com - Investing.com Canada
LeonaBio (ATHA) counsel sells 1,328 shares to cover RSU tax bill - stocktitan.net
LeonaBio (LONA) CMO covers RSU tax bill with share sale - Stock Titan
LeonaBio (LONA) CSO exercises 5,856 RSUs and sells shares for taxes - stocktitan.net
LeonaBio (NASDAQ: ATHA) files to sell 22,254 shares after RSU lapse - Stock Titan
Athira Pharma (LONA) 10K Form and SEC Filings 2026 $LONA - MarketBeat
Cantor Fitzgerald initiates Leona Bio stock with overweight rating By Investing.com - Investing.com Australia
LeonaBio initiated with an Overweight at Cantor Fitzgerald - TipRanks
Cantor Fitzgerald Initiates Coverage on LeonaBio With Overweight Rating - marketscreener.com
Cantor Fitzgerald initiates Leona Bio stock with overweight rating - Investing.com UK
LONA Technical Analysis & Stock Price Forecast - Intellectia AI
LONA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
LeonaBio Inc expected to post a loss of 85 cents a shareEarnings Preview - TradingView
LeonaBio, Inc. (prev. ATHA) (LONA) Stock Price Today | Live Chart & News - Traders Union
LeonaBio Shares Rise After Mizuho Securities Upgrade - marketscreener.com
LeonaBio (LONA) Receives Upgrade to Outperform by Mizuho | LONA Stock News - GuruFocus
Mizuho upgrades LeonaBio stock rating on breast cancer drug potential By Investing.com - Investing.com South Africa
Mizuho upgrades LeonaBio stock rating on breast cancer drug potential - Investing.com
Mizuho Securities Initiates LeonaBio(LONA.US) With Buy Rating, Announces Target Price $10 - 富途牛牛
Leonabio Inc Azioni (LONA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):